R&D pipeline progressing well
20/11/20 -"Better than expected performance of Tepezza and the upcoming launch of Amivantamab should bolster Genmab’s top line in the near term. Moreover, encouraging clinical data for pipeline assets, ..."
Pages
47
Language
English
Published on
20/11/20
You may also be interested by these reports :
20/01/26
Virbac ended 2025 on a strong note, with sales growth (at CERS) exceeding the management’s guidance that was upgraded only in October 2025. The ...
15/01/26
In late-2024, when we last teased the story of DiaSorin (BUY; Italy), a family-owned in-vitro diagnostic company specialising in immunodiagnostics ...
09/01/26
Hikma, over the years, has struggled to create shareholder wealth, perhaps because of its inability (until now) to develop biosimilars on its own. ...
31/12/25
Keeping in mind the underwhelming late-stage results of the immunology drug, amlitelimab, and a few other R&D setbacks in recent years, we have ...